Atrium

GOAL! Seattle Kraken fans to receive early boarding on Alaska Airlines

Retrieved on: 
Friday, September 17, 2021
Horizon Air, Climate Pledge Arena, Travel, Seattle Kraken, Alaska Airlines, Seattle–Tacoma International Airport, Hockey, Atrium, Marketing, Paine Field, SEA, Advertising, View, NYSE, Alaska Air Group, Pacific Northwest, Multimedia, Climate, Ice, Goal, Sale, PAE, Airline, Tourism

Starting today through the end of the season, Kraken fans who wear the teams' jersey can board early on all Alaska Airlines flights departing Seattle-Tacoma International Airport (SEA) and Paine Field (PAE) this season.

Key Points: 
  • Starting today through the end of the season, Kraken fans who wear the teams' jersey can board early on all Alaska Airlines flights departing Seattle-Tacoma International Airport (SEA) and Paine Field (PAE) this season.
  • Fans clamored this week to get a jersey when they went on sale, including many Alaska Airlines employees.
  • "We can't wait to cheer on the new team and show off our hottest new destination the Alaska Airlines' Atrium."
  • Alaska Airlines and Horizon Air are subsidiaries of Alaska Air Group (NYSE: ALK).

AtriCure to Participate at the Canaccord 41st Annual Growth Conference

Retrieved on: 
Friday, July 30, 2021
Hospitals, Health, Cardiology, Medical devices, Medical specialties, Surgery, Medicine, Cardiac arrhythmia, Atrial fibrillation, Cardiothoracic surgery, Atrium, Atrial appendage, Complication

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41st Annual Growth Conference.

Key Points: 
  • AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41st Annual Growth Conference.
  • Interested parties may access a live and archived audio webcast of the presentation by visiting the Investors section of the companys website at https://ir.atricure.com .
  • AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions.
  • Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications.

AtriCure to Announce Second Quarter 2021 Financial Results

Retrieved on: 
Wednesday, July 7, 2021
Hospitals, Health, Cardiology, Medical devices, Medical specialties, Surgery, Anatomy, Cardiac arrhythmia, Atrial fibrillation, Surgical specialties, Atrium, Atrial appendage, Cardiothoracic surgery, Laa

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release second quarter 2021 financial results on Wednesday, August 4, 2021.

Key Points: 
  • AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release second quarter 2021 financial results on Wednesday, August 4, 2021.
  • AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, August 4, 2021 to discuss its second quarter 2021 financial results.
  • A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCures corporate website at ir.atricure.com .
  • Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications.

First Naturally-designed and Personalised Bioprosthesis SingValve Set to Revolutionise Heart Valve Surgery

Retrieved on: 
Thursday, July 1, 2021
Anatomy, Heart, Medical specialties, Cardiac surgery, Valvular heart disease, Mitral valve, Cardiology, Heart valve, Atrium, Mitral valve replacement, Mitral valve repair

As a personalised heart implant, based on pre-operative patient scans, the innovation has the potential to herald a new era of heart valve surgery.

Key Points: 
  • As a personalised heart implant, based on pre-operative patient scans, the innovation has the potential to herald a new era of heart valve surgery.
  • This newly-developed mitral valve bioprosthesis, named SingValve, mimics the appearance, form and physical properties of a human mitral valve.
  • SingValve was developed as a heart valve implant that is made for the individual patient.
  • The mitral valve is situated in the left heart chamber and separates the left atrium from the left heart ventricle.

Atrium Health Recognized for Innovation, High-Quality Healthcare by Premier Inc.

Retrieved on: 
Wednesday, June 16, 2021
Other Health, Retail, Other Philanthropy, Transport, Pharmaceutical, Software, Networks, Supply chain management, Medical devices, Hospitals, Foundation, Data management, Logistics, Supply chain management, Philanthropy, Practice Management, Technology, Medical Supplies, Managed care, Health, Atrium Health, Atrium

Premier Inc. , a leading healthcare improvement company, (NASDAQ: PINC) has named Atrium Health, an integrated, nonprofit health system serving the Carolinas and Georgia, the winner of the 2021 Richard A. Norling Premier Alliance Excellence Award .

Key Points: 
  • Premier Inc. , a leading healthcare improvement company, (NASDAQ: PINC) has named Atrium Health, an integrated, nonprofit health system serving the Carolinas and Georgia, the winner of the 2021 Richard A. Norling Premier Alliance Excellence Award .
  • The Alliance Excellence Award recognizes healthcare providers that are trusted partners and valued contributors to their communities and other Premier health system members.
  • Premier has a strong, longstanding relationship with Atrium Health, built on a joint commitment to co-developing innovations, said Michael J. Alkire, President and CEO of Premier.
  • Atrium Health serves as a trusted advisor to Premier and helps to guide better outcomes both in its region and nationally.

Fifth Third Celebrates Headquarters Renewal and Expansion

Retrieved on: 
Wednesday, June 9, 2021
Banking, Professional services, Finance, Atrium, Fifth Third Center, Midtown Manhattan, Fifth Avenue

Fifth Third Bank, National Association, celebrates the completion of a new signature two-story welcome atrium, a newly designed next-generation financial center, renovated and expanded retail space, as well as the Fifth Third Museum and Fifth Third Stage.

Key Points: 
  • Fifth Third Bank, National Association, celebrates the completion of a new signature two-story welcome atrium, a newly designed next-generation financial center, renovated and expanded retail space, as well as the Fifth Third Museum and Fifth Third Stage.
  • View the full release here: https://www.businesswire.com/news/home/20210609005888/en/
    Fifth Third Bank celebrates the completion of a new signature two-story welcome atrium, a newly designed next-generation financial center, renovated and expanded retail space, as well as the Fifth Third Museum and Fifth Third Stage.
  • In 1969, Fifth Third Bank moved into its new headquarters on Fountain Square, becoming the catalyst for the revitalization of the citys historic central gathering place.
  • The Fifth Third Center Stage, the new permanent performance venue on Fountain Square, represented a $2 million gift from Fifth Third Bank to the City of Cincinnati.

Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73 (blarcamesine) for the Treatment of Cardiac Dysfunctions

Retrieved on: 
Thursday, June 3, 2021
Cardiac arrhythmia, Branches of biology, Circulatory system, Cardiovascular system, Fibrillation, Arrhythmia, Atrium, Premature ventricular contraction, Atrial fibrillation, Rhythm interpretation, Premature atrial contraction

Anavexs newest patent is expected to remain in force at least until 2038, not including any patent term extensions.

Key Points: 
  • Anavexs newest patent is expected to remain in force at least until 2038, not including any patent term extensions.
  • The new patent will expand the use of ANAVEX2-73 (blarcamesine) from neurodegenerative and neurodevelopmental disorders to a range of cardiac dysfunctions.
  • It includes cardiac arrhythmia, premature ventricular contraction (PVC), ventricular dysfunction, ventricular arrhythmia, atrial fibrillation, and atrial flutter, among others.
  • Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Global Atrial Fibrillation Epidemiology and Patient Flow - 2021 Market Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 18, 2021
Health, Cardiology, Cardiac arrhythmia, Circulatory system, Atrial fibrillation, Cardiovascular system, Cardiology, Atrium, Atrial flutter, Michel Haïssaguerre

b'The "Global Atrial Fibrillation Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis research report provides Atrial Fibrillation epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Atrial Fibrillation Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis research report provides Atrial Fibrillation epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Atrial Fibrillation patients, history of the disease at the population level (Atrial Fibrillation prevalence, Atrial Fibrillation incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Atrial Fibrillation patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Atrial Fibrillation market sizing, assessing market potential, and developing drug forecast models\nIdentify Atrial Fibrillation patients segments through age groups, gender, and disease sub-types\nEvaluate Atrial Fibrillation market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210518005832/en/\n'

Welltower Announces the Completion of Two Next Generation Medical Office Buildings Leased to Atrium Health

Retrieved on: 
Wednesday, April 28, 2021
Atrium Health, Charlotte, North Carolina, Welltower, Atrium, Carolinas Medical Center, AA3, Hospitals, Health care

b'CHARLOTTE, N.C. and TOLEDO, Ohio, April 28, 2021 /PRNewswire/ -- Welltower Inc. (NYSE: WELL) announced today the completion of two recently developed medical office buildings in Charlotte, NC, totaling over 280,000 square feet.

Key Points: 
  • b'CHARLOTTE, N.C. and TOLEDO, Ohio, April 28, 2021 /PRNewswire/ -- Welltower Inc. (NYSE: WELL) announced today the completion of two recently developed medical office buildings in Charlotte, NC, totaling over 280,000 square feet.
  • The properties were delivered in March 2021 and master leased to Atrium Health (Moody\'s: Aa3; S&P: AA-) under a 15-year triple-net lease.
  • The next-generation care provided by Atrium through these facilities will have meaningful and long-term benefits for the population it serves.
  • "The state-of-the-art facilities will serve as an anchor to the mixed-use campus which is located adjacent to Atrium Health\'s flagship Carolinas Medical Center.

AtriCure Names B. Kristine Johnson Board Chair

Retrieved on: 
Thursday, April 8, 2021
Health, FDA, Medical devices, Hospitals, Surgery, Cardiology, Biotechnology, Cardiac arrhythmia, Atrial fibrillation, Atrium, Laa, Atrial appendage

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine (Kris) Johnson has been named Board Chair.

Key Points: 
  • AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine (Kris) Johnson has been named Board Chair.
  • Ms. Johnson has served on the companys Board since May of 2017.
  • Mr. Drake, the President and CEO of ViewRay, Inc., has served on AtriCures Board since September of 2013, and has served as Board Chair since May of 2018.
  • I also want to thank Mark for his time on the Board, beginning with some of the very early days at AtriCure.